- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03951701
Evaluation of Interest of a Systematic Screening for Oncological Supportive Care Needs (DBSOS)
Evaluation of Interest of a Systematic Screening for Oncological Supportive Care
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The study will unfold in the followed day hospital's departments of the Paul Strauss Cancer Center (Strasbourg, France) : supportive care department, chemiotherapy department and radiotherapy department. The study is based on two questionnaires that include six sections : nutrition, social, psychologic, physiotherapy, pain and supportive care needs evaluation.
The first questionnaire gives information about the patient and allow to screen supportive care needs. It should be read by medical or paramedical staff who report the function of the reader and options that are proposed to the patient after reading the questionnaire.
The second questionnaire will be done after 4 to 6 weeks by a phone call from the clinical research nurse. The objective of this questionnaire is to determine what kind of care have been provided.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Strasbourg, Frankreich, 67065
- Centre PAUL STRAUSS
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patient treated for a cancer
- Age ≥ 18 years old
- Receiving treatment (chemotherapy and/or radiotherapy) in day hospital and/or supportive care department
- Able to speak, read and understand French
- Able to communicate by phone
- Written informed consent obtained from the patient
- Registration in a national health care system
Exclusion Criteria:
- Minor or protected adult
- Pregnant or breastfeeding woman
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: observation cohort
Questionnaire to assess the supportive care needs
|
Evaluation of interest of a systematic screening for oncological supportive care needs
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Evaluation of using oncological supportive cares after evaluation of supportive care needs reviewed by a professional of health, by a phone call
Zeitfenster: 4 to 6 weeks after baseline
|
Assess the percentage of using oncological supportive cares after evaluation of supportive care needs reviewed by a professional.
The use of supportive cares is evaluated with an hetero-questionnaire created for this study.
The hetero-questionnaire consists in a phone call to evaluate the evolution of each item of the self-assessment questionnaire (which includes 6 evaluations : a nutritional evaluation (10 items), a social evaluation (8 items), a psychologic evaluation (6 items), a physiological evaluation (7 items), a pain evaluation (4 items) and a supportive care needs evaluation (6 items)).
|
4 to 6 weeks after baseline
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Evaluation of initial supportive care needs by the self-assessment questionnaire
Zeitfenster: baseline
|
Assess the percentage of initial supportive care needs evaluated by the self-assessment questionnaire created for this study.
It includes evaluations : a nutritional evaluation (10 items), a social evaluation (8 items), a psychologic evaluation (6 items), a physiological evaluation (7 items), a pain evaluation (4 items) and a supportive care needs evaluation (6 items).
|
baseline
|
Assess the correlation between supportive care needs and age
Zeitfenster: This analyse will be realized at the end of the study (9 weeks after baseline)
|
Correlate the percentage of supportive care needs to age by a Pearson Chi squared test
|
This analyse will be realized at the end of the study (9 weeks after baseline)
|
Assess the correlation between supportive care needs and sexe
Zeitfenster: This analyse will be realized at the end of the study (9 weeks after baseline)
|
Correlate the percentage of supportive care needs to sexe by a Pearson Chi squared test.
|
This analyse will be realized at the end of the study (9 weeks after baseline)
|
Assess the correlation between supportive care needs and type of cancer
Zeitfenster: This analyse will be realized at the end of the study (9 weeks after baseline)
|
Correlate the percentage of supportive care needs to the type of cancer by a Pearson Chi squared test
|
This analyse will be realized at the end of the study (9 weeks after baseline)
|
Compare the percentage of using a supportive care professional judgement in regard to read and unread questionnaires by medical staff
Zeitfenster: This analyse will be realized at the end of the study (9 weeks after baseline)
|
Assess the percentage of using a supportive care when the medical staff read the completed questionnaire.
Assess the percentage of using a supportive care when the medical staff didn't read the completed questionnaire.
Then compare these values by using a T- test of Student.
|
This analyse will be realized at the end of the study (9 weeks after baseline)
|
Compare the percentage of using a supportive care professional judgement in regard to the function of the medical staff member
Zeitfenster: This analyse will be realized at the end of the study (9 weeks after baseline)
|
Assess the percentage of using a supportive care when the medical staff who read the completed questionnaire is a doctor, a nurse, or an auxiliary nurse .
Then compare these values by using a T- test of Student
|
This analyse will be realized at the end of the study (9 weeks after baseline)
|
Assess the percentage of requirement to the physician during the study
Zeitfenster: 4 to 6 weeks after baseline (by a phone call, at the same time than the hetero-questionnaire)
|
Assess the percentage of requirement to the physician during the study by asking each patient (by phone call)
|
4 to 6 weeks after baseline (by a phone call, at the same time than the hetero-questionnaire)
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Véronique FRASIE, Md, Centre PAUL STRAUSS
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- 2018-02
- 2018-A01425-50 (Andere Kennung: ANSM)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Bedarf an unterstützender Pflege
-
The Lymphoma Academic Research OrganisationNovartis; Gilead SciencesRekrutierungHämatopathologie-geeignet oder CAR-t-ZellbehandlungFrankreich
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRekrutierungKomplikationen der CAR-T-TherapieItalien
-
Stiftung Swiss Tumor InstituteKlinik Hirslanden, Zurich; Palleos Healthcare GmbHRekrutierungVom Patienten gemeldete Ergebnismessungen | CAR-T-Zell-TherapieSchweiz
-
Shanghai International Medical CenterUnbekanntFortgeschrittener solider Tumor | PD-1-Antikörper | CAR-T-ZellenChina
-
Henan Cancer HospitalFundamenta Therapeutics, Ltd.Noch keine RekrutierungAllogen, CAR-T, Protein-Sequestrierung, Nicht-Gen-editiertChina
-
Ningbo Cancer HospitalUnbekanntFortgeschrittene Malignome | PD-1-Antikörper | CAR-T-ZellenChina
-
Ruijin HospitalRekrutierung
-
Shanghai General Hospital, Shanghai Jiao Tong University...RekrutierungCAR-T-Zelle | PH-positiv ALLE | DasatinibChina
-
Insel Gruppe AG, University Hospital BernRekrutierungImpfimmunität bei Empfängern einer CAR-T-ZelltherapieSchweiz
-
Novartis PharmaceuticalsUniversity of PennsylvaniaRekrutierungLangzeitsicherheit von Patienten, die CAR-T in einer geeigneten klinischen Studie oder einem Managed Access-Programm erhaltenVereinigte Staaten, Japan, Australien, Deutschland, Spanien, Belgien, Taiwan, Italien, Kanada, Israel, Singapur, Vereinigtes Königreich, Dänemark, Finnland, Norwegen, Österreich, Niederlande, Frankreich
Klinische Studien zur Evaluation of the supportive care
-
CHU de ReimsRekrutierung
-
Memorial Sloan Kettering Cancer CenterBeendetDie Familien oder nächsten Angehörigen von Patienten, die am MSKCC wegen nichtkutaner Plattenepithelkarzinome behandelt wurden | Oberer AerodigestivtraktVereinigte Staaten
-
Skin Analytics LimitedAbgeschlossenBasalzellkarzinom | Plattenepithelkarzinom | Malignes Hautmelanom T0Vereinigte Staaten, Italien
-
Skin Analytics LimitedInnovate UKAbgeschlossen
-
Skin Analytics LimitedInnovate UKAbgeschlossen
-
Mustafa Kemalpasa Government HospitalAbgeschlossenHyperemesis gravidarum | Übelkeit am Morgen | TemperamentTruthahn
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentUnbekanntHändewaschenNiederlande
-
Buddhist Tzu Chi General HospitalAbgeschlossen
-
Duke UniversityNational Institute of Mental Health (NIMH); National Institute for Medical Research... und andere MitarbeiterRekrutierungAdhärenz, Medikamente | HIV-1-Infektion | Problem der psychischen GesundheitTansania
-
Buddhist Tzu Chi General HospitalRekrutierung